All In Biotech

Drug Trial Radar · NCT05714969

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

A Phase 2b, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of TAK-755 (rADAMTS13) With Minimal to No Plasma Exchange (PEX) in the Treatment of Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

29

Actual

Start

Jul 21, 2023

Primary completion

Apr 16, 2026

Study completion Apr 16, 2026

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
Collaborators
Takeda Development Center Americas, Inc.
First posted
Feb 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study of TAK-755 in adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP). The main aim of this study is to determine the percentage of participants with a clinical (Part 1) or platelet (Part 2) response without plasma exchange during the study. Participants who have an acute attack of iTTP will receive TAK-755 and immunosuppressive therapy during their stay at the hospital until they achieve a clinical response in Part 1 or platelet response in Part 2. Participants will also be treated with TAK-755 for an additional time of up to 6 weeks after the acute phase. In total, participants will stay in the study for approximately 3 months.

Conditions

  • Thrombotic Thrombocytopenic Purpura (TTP)

Interventions

  • TAK-755Biological

    TAK-755 IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Event of Special Interest (AESIs) After Receiving any Dose of Investigational Product (IP)Time frame: Through study completion, approximately 12 weeks

Locations

22 sites in 6 countries. Site status is shown where the registry gives one.

  • University of Florida - Shands

    Gainesville, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • University of Minnesota Clinical Research Unit

    Minneapolis, Minnesota

  • Rutgers University

    New Brunswick, New Jersey

  • Weill Cornell

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Leo Jenkins Cancer Center/ECU School of Medicine

    Greenville, North Carolina

  • Ohio State University

    Columbus, Ohio

  • University of Utah Health Sciences Center

    Salt Lake City, Utah

  • Versiti Wisconsin, Inc.

    Milwaukee, Wisconsin

  • AKH - Medizinische Universitat Wien

    Vienna, Austria

  • General Hospital of Thessaloniki "G. Papanikolaou"

    Thessaloniki, Greece

  • Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino

    Torino, Italy

  • Hospital General Universitario Gregorio Maranon

    Madrid, Spain

  • Hospital Universitari i Politecnic La Fe

    Valencia, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Sevilla, Spain

  • Hospital de Cruces

    Barakaldo, Vizcaya, Spain

  • University College London Hospital

    London, Greater London, United Kingdom

  • Royal Liverpool University Hospital

    Liverpool, Merseyside, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.